News

Descubre las últimas noticias de Devicare

Devicare signs three business agreements for Lit-Control® in Europe and North Africa

Device continues its international expansion, positioning its brand as a benchmark in innovative therapeutic solutions in urology. After taking the leap into the US market in May, the company has signed three new agreements to market Lit-Control® in the United Kingdom, Malta and Algeria. In total, Devicare is now present in 34 countries. The partners in these countries are the pharmaceutical companies Purple Orchid Health, Vivian Corporation and Pharm and Phyt, respectively.

Read More

Devicare obtiene 500.000 euros adicionales de la línea Innova Global de Avançsa

Devicare ha firmado un nuevo préstamo participativo de 500.000 euros de la línea Innova Global de Avançsa, adscrita al Departamento de Empresa y Conocimiento, para acelerar el crecimiento internacional de la compañía que desarrolla nuevas soluciones terapéuticas en urología. En 2017 Avançsa ya apostó por este proyecto empresarial aportando una financiación de 2 millones de euros tras valorar su alto…

Read More

Devicare abre una ronda de ‘crowdfunding’ de 1,5 millones de euros

Devicare quiere acelerar su crecimiento y para ello ha puesto en marcha una campaña de crowdfunding de 1,5 millones de euros en la plataforma Capital Cell. En una semana ya se ha conseguido el 39% del objetivo. La cantidad mínima a invertir es 1.000 euros. Devicare ha desarrollado una solución para el tratamiento no quirúrgico de la litiasis renal o…

Read More

Devicare launches Lit-Control® in the US with Diem Labs

Devicare is taking the leap into the US healthcare market with its new partner Diem Labs, LLC to introduce an innovative digital medical solution (DTx) in the urology field in the country. The official launch of Lit-Control® take place in the American Urological Association Annual Meeting (BOOTH 3440), held from 3 to 6 May in Chicago, which features the company's CEO, Rosendo Garganta.

Read More

Devicare participates in the leading lithiasis event in Spain and presents the results of the 'Double J' trial

Devicare participated in the National Meeting of the Lithiasis, Endourology, Laparoscopy and Robotics Groups (LELR), held on 24 and 25 January in Palma de Mallorca. The plenary sessions focused on the medical and surgical handling of urinary lithiasis which affects 10% of the Spanish population. The final results of the “Double J” clinical trial led by specialists from nine leading Spanish hospitals renowned for urology care and sponsored by Devicare were also presented during the event.

Read More

The 'Double J' clinical trial wins the Pedro Arregui award from the Spanish Urological Association

During the 19th National Meeting of the Lithiasis, Endourology and Robotics Groups organised by the Spanish Urological Association on 24 and 25 January in Palma de Mallorca, Dr Jaime Fernández-Concha was recognised on behalf of the research team for the Multicenter, Controlled and Randomized clinical trial on urinary pH monitoring and nutraceutical intervention in the prevention of ureteral stent calcification, with the Pedro Arregui Award for the best scientific poster communication. Apart from Dr Fernández-Concha, doctors s Carlos Torrecilla (Bellvitge University Hospital)...

Read More

Devicare announces the positive results of the clinical trial with Lit-Control® to prevent the encrustation of catheters in patients with lithiasis

Devicare and nine leading Spanish hospitals in urology have successfully completed the clinical trial which demonstrates the efficacy of the combined use of a medical device (Lit-Control® pH Meter) and a nutraceutical (Lit-Control® pH Down) to prevent the encrustation of double J catheters by monitoring urinary pH and supplying phytates (crystallisation inhibitors)...

Read More

Dr Carlos Torrecilla: “We have the solution to prevent the encrustation of double J catheters”

Dr Carlos Torrecilla, director of the Lithiasis Unit of the Bellvitge University Hospital and national coordinator of the Lithiasis and Endourology Group of the Spanish Association of Urology, is the principal investigator of a clinical trial sponsored by Devicare conducted in nine Spanish university hospitals (Bellvitge, La Paz, Río Hortega, Puigvert Foundation, San Cecilio, Valme, Álvaro Cunqueiro, La Fe and Santiago de Compostela)...

Read More

Devicare and Exeltis signed an agreement to market the Lit-Control in Spain

The multinational company Exeltis and the digital therapeutics company Devicare have signed an agreement to market the Lit-Control® family of products in Spain. Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment. This collaboration brings together Exeltis' expertise and excellence in health care with Devicare's experience in product development, intellectual property and clinical research...

Read More
Menu
Sensor pH 1

Publications numbers

CA2938155 (A1)

CN106104265 (A)

EP3106865 (A1)

IN201617025892 (A)(A2)

JP2017505443 (A)

KR20160119096 (A)

MX2016010017 (A)

WO2015121516 (A1)

US10067085 (B2)

US2016021926 (A)

×
Sensor pH 2

Publications numbers

ES2597129 (B1)

WO2017009510 (A1)

CN107850565 (A)

EP3324177 (A1)

IN201717045992 (A)

JP2018520355 (A)

KR20180029044 (A)

WO2017009510 (A1)

US10254243 (B2)

×
Lector pH

Publications numbers

EP2515104 (A2)

ES1071520 (U)

WO2011073484 (A2)

US2016061813 (A1)

×
Lit Control - pH Up

Publications numbers

EP3130337 (B1)

ES2486442 (B1)

WO2015150609 (A1)

×
Lit Control - pH Up

Publications numbers

CA2950036 (A1)

CN106456646 (A)

EP3150208 (A1)

ES2552706 (A1)

IN201617039469 (A)

JP2017516791 (A)

KR20170005020 (A)

MX2016015577 (A1)

WO2015181412 (A1)

US10149851 (B2)

×
Lit Control - pH Down

Publications numbers

CN106232143 (A)

EP3130352 (A1)

ES2486441 (A1)

IN201617031655 (A)

KR20160133002 (A)

MX2016012302 (A)

WO2015150608 (A1)

US20170106032 (A1)

US2019216873 (A1)

×
Lit Control - pH Balance

Publications numbers

CN106535906 (A)

EP3162376 (A1)

ES2555166 (A1)

IN201617042534 (A)

KR20170015360 (A)

MX2016016995 (A)

WO2015197892 (A1)

US20170128469 (A1)

×
Sensor pH 1-OLD

Países

Publications numbers

Canadá

CA2938155 (A1)

China

CN106104265 (A)

Europa

EP3106865 (A1)

España

ES2542927 (A2)

Índia

NP

Japón

JP2017505443 (A)

Corea del Sur

KR20160119096 (A)

Méjico

MX2016010017 (A)

Internacional

WO2015121516 (A1)

Estados Unidos

US2017010237 (A1)

×
Sensor pH 2

Países

Publications numbers

España

ES2597129 (A1)

Internacional

WO2017009510 (A1)

×
Sensor pH 1

Países

Publications numbers

Europa

EP2515104 (A2), (A4)

España

ES1071520 (U), (Y)

Internacional

WO2011073484 (A2), (A3)

Estados Unidos

US2013032494 (A1)

Estados Unidos

US2016061813 (A1)

×
Lit Control - pH Up

Países

Publications numbers

Europa

EP3130337 (A1)

España

ES2486442 (A1)

Internacional

WO2015/150609 (A1)

×
Lit Control - pH Up

Países

Publications numbers

Canadá

CA2950036 (A1)

China

CN106456646 (A)

Europa

EP3150208 (A1)

España

ES2552706 (A1)

Índia

NP

Japón

JP2017516791 (A)

Corea del Sur

KR20170005020 (A)

Méjico

NP

Internacional

WO2015/181412 (A1)

Estados Unidos

US2017143724 (A1)

×
Lit Control - pH Down

Países

Publications numbers

China

CN106232143 (A)

Europa

EP3130352 (A1)

España

ES2486441 (A1)

Índia

NP

Corea del Sur

KR20160133002 (A)

Méjico

MX2016012302 (A)

Internacional

WO2015/150608 (A1)

Estados Unidos

US2017/0106032 (A1)

×
Lit Control - pH Balance

Países

Publications numbers

China

CN106535906 (A)

Europa

EP3162376 (A1)

España

ES2555166 (A1)

Índia

NP

Corea del Sur

KR20170015360 (A)

Méjico

MX2016016995 (A)

Internacional

WO2015/197892 (A1)

Estados Unidos

US2017/0128469 (A1)

×
Rosendo Garganta - CEO

Board Member and Private Investor in different biotech start-ups.
Former President of Medical Devices Committee at Catalonia Association of Biotech Companies.
Master in Business Administration.
Master in International Business.
Master in Entrepreneurship & Innovation.
BSc. Industrial Engineering.
BSc. Electronic Engineering.
+10 years of experience in Business Development in MD companies.

×
Marta Aznar - QARA Director

Marta Aznar - QARA Director

QMS Manager at Mesoestetic.
Deputy Quality Manager at SANJO.
PDD at IESE.
Master in Business Administration.
BSc in Chemical Engineering.
+15 years of experience managing QA and QC in different industrial companies (pharma and automotive sectors)

×
Xavi Peris - Marketing & Sales Director

Xavi Peris - Marketing & Sales Director

Marketing Director at Rubió.
Marketing Director at Lacer.
Master in Business Administration.
BSc in Law.
+25 years in strategic marketing positions managing budgets +€20 M, sales force +300 representatives, and having launched +10 products to the market in Urology and Cardiology.

×
David Pascual - Operations Director

David Pascual - Operations Director

+15 Years of experience in strategic positions regarding prototype and production in prestigious companies as Sanyo or Ateknea.
Master’s in production management.
BSc Electronic Engineering.

×
Jordi Cuñe - Medical Director

Jordi Cuñe - Medical Director

Scientific Director at AB-Biotics
PhD in Microbiology
BSc in Food Science and Technology
BSc in Biology
+15 years of experience in strategic research positions managing the development of innovative nutraceuticals and monitoring clinical trials

×
Francisco Cabezas - Financial Director

Francisco Cabezas - Financial Director

Financial Director at Medichem.
Financial Director at Combino.
Master in Financial Management.
BSc in Business Administration.
+20 years of experience in strategic financial positions managing budgets of +€80 M, investments of +€50 M and being in charge of the M&A of Combino by Medichem Group.

×
Javier Haro - R&D Director

Javier Haro - R&D Director

System Manager at Ficosa.
R&D Manager at FTE Maximal.
R&D Manager at SANYO.
Master in Project Management.
BSc in Telecom. Engineering.
+20 years of experience in strategic R&D positions managing the development of successful products and creating R&D teams from scratch to +120 people.

×